{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:40:36Z","timestamp":1792554036812,"version":"4.5.0"},"reference-count":0,"publisher":"Press of International Journal of Ophthalmology (IJO Press)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Ophthalmol"],"published-print":{"date-parts":[[2022,6,18]]},"abstract":"<jats:p>AIM: To evaluate the cost-utility of iStent inject\u00ae with cataract surgery vs cataract surgery alone in patients with mild-to-moderate primary open angle glaucoma (POAG) in the Japanese setting from a public payer's perspective.\nMETHODS: A Markov model was adapted to estimate the cost-utility of iStent inject\u00ae plus cataract surgery vs cataract surgery alone in one eye in patients with mild-to-moderate POAG over lifetime horizon from the perspective of Japanese public payer. Japanese sources were used for patients' characteristics, clinical data, utility, and costs whenever available. Non-Japanese data were validated by Japanese clinical experts.\nRESULTS: In the probabilistic base case analysis, iStent inject\u00ae with cataract surgery was found to be cost-effective compared with cataract surgery alone over a lifetime horizon when using the \u00a55 000 000\/quality-adjusted life year (QALY) willingness-to-pay threshold. The incremental cost-utility ratio (ICUR) was estimated to be \u00a51 430 647\/QALY gained and the incremental cost-utility ratio (ICER) was estimated to be \u00a512 845 154\/blind eye avoided. iStent inject\u00ae with cataract surgery vs cataract surgery alone was found to increase costs (\u00a51 025 785 vs \u00a5933 759, respectively) but was more effective in increasing QALYs (12.80 vs 12.74) and avoiding blinded eyes (0.133 vs 0.141). The differences in costs were mainly driven by costs of primary surgery (\u00a5279 903 vs \u00a5121 349). In the scenario analysis from a societal perspective, which included caregiver burden, iStent inject\u00ae with cataract surgery was found to dominate cataract surgery alone.\nCONCLUSION: The iStent inject\u00ae with cataract surgery is a cost-effective strategy over cataract surgery alone from the public payer's perspective and cost-saving from the societal perspective in patients with mild-to-moderate POAG in Japan.<\/jats:p>","DOI":"10.18240\/ijo.2022.06.13","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T07:32:39Z","timestamp":1653982359000},"page":"954-961","source":"Crossref","is-referenced-by-count":11,"title":["iStent inject\u00ae and cataract surgery for mild-to-moderate primary open angle glaucoma in Japan: a cost-utility analysis"],"prefix":"10.18240","volume":"15","author":[{"name":"Unit of Public Health and Preventive Medicine, Yokohama City University School of Medicine, Yokohama 236-0027, Japan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ataru","family":"Igarashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Ophthalmology, Kitasato University Hospital, Kanagawa 252-0375, Japan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Market Access and Medical Marketing, Glaukos Singapore, Singapore 068896, Singapore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Falvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Global Health Economics, Glaukos Corp, California 92672, USA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Health Economics and Outcomes Research, Creativ-Ceutical, Paris 75008, France","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Ueyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Health Economics and Outcomes Research, Creativ-Ceutical, Tokyo 108-6028, Japan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Health Economics and Outcomes Research, Creativ-Ceutical, Tokyo 108-6028, Japan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7543","container-title":["International Journal of Ophthalmology"],"original-title":[],"link":[{"URL":"http:\/\/ies.ijo.cn\/en_publish\/2022\/6\/20220613.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T07:32:57Z","timestamp":1653982377000},"score":1,"resource":{"primary":{"URL":"http:\/\/ies.ijo.cn\/gjyken\/ch\/reader\/view_abstract.aspx?file_no=20220613&flag=1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,18]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,18]]}},"URL":"https:\/\/doi.org\/10.18240\/ijo.2022.06.13","relation":{},"ISSN":["2222-3959","2227-4898"],"issn-type":[{"value":"2222-3959","type":"print"},{"value":"2227-4898","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,18]]}}}